Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 3
1973 1
1978 1
1980 1
1982 4
1983 2
1984 4
1985 7
1986 1
1987 1
1988 4
1989 3
1990 2
1991 4
1992 1
1993 3
1994 2
1995 9
1996 5
1997 3
1998 8
1999 14
2000 10
2001 17
2002 9
2003 12
2004 7
2005 12
2006 9
2007 11
2008 23
2009 27
2010 38
2011 45
2012 30
2013 38
2014 30
2015 40
2016 51
2017 64
2018 63
2019 68
2020 66
2021 52
2022 65
2023 58
2024 53
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

863 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.
Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, Gupta S, Vanderbilt C, Purohit TA, Liu M, Kansler E, Nixon BG, Chen YB, Makarov V, Blum KA, Attalla K, Weng S, Salmans ML, Golkaram M, Liu L, Zhang S, Vijayaraghavan R, Pawlowski T, Reuter V, Carlo MI, Voss MH, Coleman J, Russo P, Motzer RJ, Li MO, Leslie CS, Chan TA, Hakimi AA. Krishna C, et al. Among authors: voss mh. Cancer Cell. 2021 May 10;39(5):662-677.e6. doi: 10.1016/j.ccell.2021.03.007. Epub 2021 Apr 15. Cancer Cell. 2021. PMID: 33861994 Free PMC article.
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Lee CH, et al. Among authors: voss mh. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17. J Clin Oncol. 2022. PMID: 35298296 Free PMC article. Clinical Trial.
Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.
Tang C, Xie AX, Liu EM, Kuo F, Kim M, DiNatale RG, Golkaram M, Chen YB, Gupta S, Motzer RJ, Russo P, Coleman J, Carlo MI, Voss MH, Kotecha RR, Lee CH, Tansey W, Schultz N, Hakimi AA, Reznik E. Tang C, et al. Among authors: voss mh. Cell Metab. 2023 Aug 8;35(8):1424-1440.e5. doi: 10.1016/j.cmet.2023.06.005. Epub 2023 Jul 5. Cell Metab. 2023. PMID: 37413991 Free PMC article.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK, Albiges L, Tomczak P, Suárez C, Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Pal SK, et al. Among authors: voss mh. Lancet. 2023 Jul 15;402(10397):185-195. doi: 10.1016/S0140-6736(23)00922-4. Epub 2023 Jun 5. Lancet. 2023. PMID: 37290461 Free PMC article. Clinical Trial.
Reply by Authors.
Reese SW, Khaleel S, Silagy A, Xie A, Eismann L, Vazquez-Rivera K, Oparanozie A, Patil S, Coleman J, Motzer R, Kotecha RR, Russo P, Voss MH, Hakimi AA. Reese SW, et al. Among authors: voss mh. J Urol. 2023 Aug;210(2):279-280. doi: 10.1097/JU.0000000000003549.02. Epub 2023 Aug 1. J Urol. 2023. PMID: 37416962 No abstract available.
The effector program of human CD8 T cells supports tissue remodeling.
Delacher M, Schmidleithner L, Simon M, Stüve P, Sanderink L, Hotz-Wagenblatt A, Wuttke M, Schambeck K, Ruhland B, Hofmann V, Bittner S, Ritter U, Pant A, Helbich SS, Voss M, Lemmermann NA, Bessiri-Schake L, Bohn T, Eigenberger A, Menevse AN, Gebhard C, Strieder N, Abken H, Rehli M, Huehn J, Beckhove P, Hehlgans T, Junger H, Geissler EK, Prantl L, Werner JM, Schmidl C, Brors B, Imbusch CD, Feuerer M. Delacher M, et al. Among authors: voss m. J Exp Med. 2024 Feb 5;221(2):e20230488. doi: 10.1084/jem.20230488. Epub 2024 Jan 16. J Exp Med. 2024. PMID: 38226976 Free PMC article.
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Fitzgerald KN, et al. Among authors: voss mh. Eur Urol. 2024 Aug;86(2):90-94. doi: 10.1016/j.eururo.2024.04.025. Epub 2024 May 22. Eur Urol. 2024. PMID: 38782695 Clinical Trial.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Herati RS, et al. Among authors: voss mh. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. Nat Immunol. 2022. PMID: 35902637 Free PMC article.
863 results